Abstract | OBJECTIVE: METHODS: RESULTS: Inhibition of TAFI in the Angiotensin II model resulted in a decrease in the mortality associated with AAA rupture (from 40.0% to 16.6% with MA-TCK26D6 (log-rank Mantel Cox test p = 0.16), and 8.3% with UK-396082 (log-rank Mantel Cox test p = 0.05)). Inhibition of plasmin-mediated TAFI activation reduced the incidence of AAA from 52.4% to 30.0%. However, late treatment with MA-TCK26D6 once AAA were already established had no effect on the progression of AAA in this model. CONCLUSIONS: The formation of intra-mural thrombus is responsible for the dissection and early rupture in the angiotensin II model of AAA, and this process can be prevented through inhibition of TAFI. Late treatment with a TAFI inhibitor does not prevent AAA progression. These data may indicate a role for inhibition of plasmin-mediated TAFI activation in the early stages of AAA development, but not in its progression.
|
Authors | Katherine Bridge, Charlotte Revill, Fraser Macrae, Marc Bailey, Nadira Yuldasheva, Stephen Wheatcroft, Roger Butlin, Richard Foster, D Julian Scott, Ann Gils, Robert Ariens |
Journal | PloS one
(PLoS One)
Vol. 12
Issue 5
Pg. e0177117
( 2017)
ISSN: 1932-6203 [Electronic] United States |
PMID | 28472123
(Publication Type: Journal Article)
|
Chemical References |
- Apolipoproteins E
- Carboxypeptidase B2
- Cpb2 protein, mouse
- Fibrinolysin
|
Topics |
- Animals
- Aortic Aneurysm, Abdominal
(pathology)
- Apolipoproteins E
(genetics)
- Carboxypeptidase B2
(antagonists & inhibitors, metabolism)
- Disease Models, Animal
- Disease Progression
- Fibrinolysin
(metabolism)
- Male
- Mice
- Mice, Knockout
|